195 related articles for article (PubMed ID: 37891626)
21. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
22. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
25. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre.
Keyes AM; Kelly ME; McInerney N; Khan MF; Bolger JC; McCormack E; Grundy J; McCormack O; MacHale J; Conneely J; Brennan D; Cahill R; Shields C; Moran B; Mulsow J
Eur J Surg Oncol; 2021 Sep; 47(9):2358-2362. PubMed ID: 33895028
[TBL] [Abstract][Full Text] [Related]
26. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
27. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
[No Abstract] [Full Text] [Related]
28. An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Mercier F; Passot G; Bonnot PE; Cashin P; Ceelen W; Decullier E; Villeneuve L; Walter T; Levine EA; Glehen O; ;
World J Surg; 2022 Jun; 46(6):1336-1343. PubMed ID: 35286418
[TBL] [Abstract][Full Text] [Related]
29. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
30. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN
J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572
[TBL] [Abstract][Full Text] [Related]
31. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
[TBL] [Abstract][Full Text] [Related]
32. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.
Shaltiel T; Solomon D; Pletcher ER; Golas BJ; Magge DR; Sarpel U; Labow DM; Cohen NA
Surg Endosc; 2022 Aug; 36(8):6153-6161. PubMed ID: 35080674
[TBL] [Abstract][Full Text] [Related]
33. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
[TBL] [Abstract][Full Text] [Related]
35. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
36. Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis.
Kubi B; Nudotor R; Fackche N; Nizam W; Cloyd JM; Grotz TE; Fournier KF; Dineen SP; Powers BD; Veerapong J; Baumgartner JM; Clarke CN; Patel SH; Lambert LA; Abbott DE; Vande Walle KA; Raoof M; Lee B; Maithel SK; Staley CA; Johnston FM; Greer JB
Ann Surg Oncol; 2021 Aug; 28(8):4499-4507. PubMed ID: 33507449
[TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
38. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
[TBL] [Abstract][Full Text] [Related]
39. Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Sun BJ; Yue TM; Xu N; Fowler C; Lee B
Ann Surg Oncol; 2023 Dec; 30(13):8156-8165. PubMed ID: 37684372
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Weksler Y; Hoffman A; Green E; Kyzer M; Nevo N; Gerstenhaber F; Greenberg R; Klausner JM; Gutman M; Lahat G; Berger Y; Geva R; Nizri E
Surg Oncol; 2022 Sep; 44():101848. PubMed ID: 36126349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
